Product Description
Resminostat is an orally administered histone deacetylase (HDAC) inhibitor that potentially represents a novel therapy for a broad spectrum of oncology indications, both in monotherapy and particularly in combination with other anti-cancer drugs. (Sourced from: https://www.4sc.com/product-pipeline/resminostat/)
Mechanisms of Action: HDAC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: 4SC
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, France, Germany, Greece, Italy, Japan, Netherlands, Poland, Spain, Switzerland, United Kingdom
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Mycosis Fungoides|Sezary Syndrome|T-Cell Cutaneous Lymphoma
Phase 1: Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RESMAIN | P2 |
Completed |
Mycosis Fungoides|Sezary Syndrome|T-Cell Cutaneous Lymphoma |
2023-03-01 |
|
| jRCT2071210134 | P1 |
Completed |
Lymphoma |
2022-09-30 |
|
| 4SC-201-7-2020 | P1 |
Completed |
Mycosis Fungoides|Sezary Syndrome|T-Cell Cutaneous Lymphoma |
2022-01-19 |
42% |